Rhumbline Advisers Stoke Therapeutics, Inc. Transaction History

Rhumbline Advisers

$113 Billion
Q2 2025

A detailed history of Rhumbline Advisers transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 66,419 shares of STOK stock, worth $898,649. This represents 0.0% of its overall portfolio holdings.

Number of Shares

66,419

Previous 49,599 33.91%

Holding current value

$898,649

Previous $329,000 128.88%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 12, 2025	BUY	$5.9 - $11.84 $99,238 - $199,148	16,820 Added 33.91%	66,419 $753,000
Q1 2025 Apr 08, 2025	BUY	$6.65 - $12.74 $1,496 - $2,866	225 Added 0.46%	49,599 $357,000
Q4 2024 May 29, 2025	SELL	$10.8 - $13.92 $2,430 - $3,132	-225 Reduced 0.45%	49,374 $544,000
Q4 2024 Jan 30, 2025	BUY	$10.8 - $13.92 $30,099 - $38,795	2,787 Added 5.98%	49,374 $544,000
Q3 2024 Nov 12, 2024	SELL	$12.24 - $15.92 $15,581 - $20,266	-1,273 Reduced 2.66%	46,587 $572,000
Q2 2024 Aug 01, 2024	BUY	$11.03 - $17.52 $66,069 - $104,944	5,990 Added 14.31%	47,860 $646,000
Q1 2024 May 09, 2024	BUY	$4.12 - $14.17 $3,703 - $12,738	899 Added 2.19%	41,870 $565,000
Q4 2023 Feb 08, 2024	SELL	$3.37 - $5.4 $128 - $205	-38 Reduced 0.09%	40,971 $215,000
Q3 2023 Nov 09, 2023	SELL	$3.78 - $11.99 $4,407 - $13,980	-1,166 Reduced 2.76%	41,009 $161,000
Q2 2023 Aug 08, 2023	BUY	$7.93 - $13.82 $60,093 - $104,727	7,578 Added 21.9%	42,175 $448,000
Q1 2023 May 11, 2023	BUY	$7.65 - $10.38 $3,105 - $4,214	406 Added 1.19%	34,597 $288,000
Q4 2022 Feb 14, 2023	BUY	$7.07 - $15.69 $3,358 - $7,452	475 Added 1.41%	34,191 $316,000
Q3 2022 Nov 10, 2022	BUY	$12.56 - $22.53 $23,424 - $42,018	1,865 Added 5.86%	33,716 $433,000
Q2 2022 Aug 11, 2022	BUY	$10.36 - $23.93 $129,562 - $299,268	12,506 Added 64.65%	31,851 $421,000
Q1 2022 May 12, 2022	BUY	$17.19 - $26.1 $23,412 - $35,548	1,362 Added 7.57%	19,345 $407,000
Q4 2021 Feb 10, 2022	SELL	$18.11 - $30.72 $6,084 - $10,321	-336 Reduced 1.83%	17,983 $431,000
Q3 2021 Nov 12, 2021	BUY	$23.65 - $34.44 $20,078 - $29,239	849 Added 4.86%	18,319 $466,000
Q2 2021 Aug 05, 2021	BUY	$30.53 - $41.09 $59,930 - $80,659	1,963 Added 12.66%	17,470 $588,000
Q1 2021 May 06, 2021	SELL	$36.08 - $69.81 $5,953 - $11,518	-165 Reduced 1.05%	15,507 $602,000
Q4 2020 Feb 10, 2021	BUY	$33.62 - $61.93 $30,594 - $56,356	910 Added 6.16%	15,672 $971,000
Q3 2020 Nov 12, 2020	SELL	$22.23 - $37.48 $47,016 - $79,270	-2,115 Reduced 12.53%	14,762 $494,000
Q2 2020 Aug 13, 2020	SELL	$20.26 - $29.73 $67,688 - $99,327	-3,341 Reduced 16.52%	16,877 $402,000
Q1 2020 May 06, 2020	BUY	$16.8 - $34.15 $206,287 - $419,327	12,279 Added 154.67%	20,218 $463,000
Q4 2019 Feb 05, 2020	BUY	$20.01 - $30.79 $158,859 - $244,441	7,939 New	7,939 $225,000

Others Institutions Holding STOK

# of Institutions

140

Shares Held

57.6M

Call Options Held

2.7K

Put Options Held

57.4K

View Full List

About Stoke Therapeutics, Inc.

Ticker STOK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,419,300
Market Cap $533M
Description
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...

More about STOK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Stoke Therapeutics, Inc. Transaction History